Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of a Reduced-Antigen Tdap Vaccine in Individuals Aged 6 Years and Above
NCT07418372Phase 2Not yet recruiting
- Sponsor
- Institute of Medical Biology
- Start
- Mar 2026
- Primary completion
- Aug 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tetanus toxoid + diphtheria toxoid + acellular pertussis vaccine (reduced antigen content) in Tetanus, diphtheria, pertussis, sponsored by Institute of Medical Biology. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
tetanus toxoid + diphtheria toxoid + acellular pertussis vaccine (reduced antigen content)
03
Conditions
Tetanusdiphtheriapertussis
Beyond the preview
Go deeper on NCT07418372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07418372.